References
Armand P . Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393–3400.
Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 443–445.
Haverkos BM, Schowinksy J, Kaplan J, Kamdar M, Kanate AS, Saad A et al. Checkpoint blockade for treatment of relapsed lymphoma following allogeneic hematopoietic cell transplant: use may be complicated by onset of severe acute graft versus host disease. Blood 2016; 128: 22 (abstract 1163).
Schoch LK, Borrello I, Fuchs EJ, Bolanos-Meade J, Huo JS, Gojo I et al. Checkpoint inhibitor therapy and graft versus host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post transplant cyclophosphamide. Blood 2016; 128: 22 (abstract 4571).
Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin’s lymphoma. Blood 2017; 129: 2471–2478.
Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales M-A et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 2017; 129: 1380–1388.
Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an INF-gamma-dependent mechanism. J Immunol 2003; 171: 1272–1277.
Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013; 122: 3062–3073.
Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M et al. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest 2017; 127: 1960–1977.
Fuji S, Shindo T . Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investig 2016; 3: 70–77.
Acknowledgements
Author contributions
YO analyzed data, drafted the paper and contributed analytical tools; TT designed research and wrote the paper; KY performed research and analyzed data; and AT designed research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
YO reports personal fees from Novartis Pharma KK and Sanofi KK, outside the submitted work; AT reports grants from Bristol-Myers, Pfizer, Chugai Pharmaceutical, Daiichi Sankyo and Sumitomo Dainippon-Pharma, and personal fees from Taiho Pharmaceutical, Rohto Pharmaceutical, Celgene, Novartis, Ohtsuka Pharmaceutical and Sysmex, outside the submitted work; TT and KY declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Oshima, Y., Tanimoto, T., Yuji, K. et al. Association between GvHD and nivolumab in the FDA adverse event reporting system. Bone Marrow Transplant 52, 1463–1464 (2017). https://doi.org/10.1038/bmt.2017.158
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.158
- Springer Nature Limited
This article is cited by
-
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
Annals of Hematology (2021)
-
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Experimental Hematology & Oncology (2019)
-
Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas
International Journal of Hematology (2019)